Epigenetic targeting in pancreatic cancer

Jasmijn G M van Kampen; Monica A J Marijnissen-van Zanten; Femke Simmer; Winette T A van der Graaf; Marjolijn J L Ligtenberg; Iris D Nagtegaal

doi:10.1016/j.ctrv.2013.12.002

Epigenetic targeting in pancreatic cancer

Cancer Treat Rev. 2014 Jun;40(5):656-64. doi: 10.1016/j.ctrv.2013.12.002. Epub 2014 Jan 3.

Authors

Jasmijn G M van Kampen¹, Monica A J Marijnissen-van Zanten², Femke Simmer³, Winette T A van der Graaf⁴, Marjolijn J L Ligtenberg⁵, Iris D Nagtegaal⁶

Affiliations

¹ Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Department of Urology 267, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: [email protected].
² Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: [email protected].
³ Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: [email protected].
⁴ Department of Medical Oncology 452, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: [email protected].
⁵ Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Department of Human Genetics 855, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: [email protected].
⁶ Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: [email protected].

PMID: 24433955
DOI: 10.1016/j.ctrv.2013.12.002

Abstract

The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.

Keywords: DNA methyltransferase inhibitor; Epigenetics; Histone deacetylase inhibitor; Histone methyltransferase inhibitor; MicroRNA; Pancreatic cancer; Therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Clinical Trials as Topic
DNA Methylation / drug effects*
DNA Methylation / genetics
Epigenesis, Genetic / drug effects*
Epigenesis, Genetic / genetics
Female
Forecasting
Gene Expression Regulation, Neoplastic
Histone Deacetylase Inhibitors / therapeutic use
Histone Methyltransferases
Histone-Lysine N-Methyltransferase / antagonists & inhibitors*
Histone-Lysine N-Methyltransferase / therapeutic use
Humans
Male
MicroRNAs / drug effects
MicroRNAs / genetics
Molecular Targeted Therapy / methods
Molecular Targeted Therapy / trends*
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / genetics
Pancreatic Neoplasms / pathology
Treatment Outcome
Tumor Microenvironment / drug effects

Substances

Antineoplastic Agents
Histone Deacetylase Inhibitors
MicroRNAs
Histone Methyltransferases
Histone-Lysine N-Methyltransferase